제10회 대한폐고혈압학회 학술대회
July 11-12, 2025
Coex Magok, Seoul, Korea
Abdullah M. Aldalaan
President, Saudi Association for PH, Saudi Arabia
P2-1. PAH; Where Research Leads to Treatment Advances
CVAlkhodair Abdullah
SAPH Board Member, Saudi Arabia
P2-3. Percutaneous Interventional Modalities to Treat PH
CVHiromi Matsubara
Okayama Medical Center, Japan
P2-4. How to cooperate on the research of PH in Asia Pacific region
CVDharmendra Kumar Khatri
Nims Jaipur, India
P4-1. AI-Assisted Echocardiography for Early Detection of Pulmonary Arterial Hypertension in Primary Care: A Multicenter Prospective Study
CVCze Ci Chan
Linkou Chang Gung Memorial Hospital, Taiwan
P4-2. Real-World Experience with Sotatercept in PAH: Hematologic Effects and Safety Considerations
CVZizheng Yi
The First Affiliated Hospital, Sun Yat-sen Univ., China
P4-3. Pulmonary Hypertension with Multifactorial Pathogenesis: A Case Report Dominated by Autoantibodies and Cardiomyopathy-Associated Genes
CVKilYoon Pack
Gachon Univ., Korea
P4-4. Evaluation of Echocardiographic Validity for Estimating PVR and Mean PAP Compared to Right Heart Catheterization in Suspected Pulmonary Hypertension
CVDuk Woo Lee
Seoul National Univ., Korea
P4-5. The effect of Udenafil to improve exercise capacity for Fontan patients
CVSang Hyun Lee
Pusan National Univ., Korea
P6-1. Pathophysiology and diagnosis of Eisenmenger syndrome
CVGi Beom Kim
Seoul National Univ., Korea
P6-2. Selective pulmonary vasodilator for Eisenmenger syndrome
CVJung Yoon Kim
Sejong General Hospital, Korea
P6-3. Treat and repair strategy for adult CHD with PAH
CVKyung-Jin Ahn
Gachon Univ., Korea
P6-4. Pregnancy and delivery in female with Eisenmenger syndrome
CVHang Zhang
Nanjing Medical Univ., China
P7-2. Pulmonary Artery Denervation (PADN): an innovative Pulmonary Hypertension Therapy
CVPhuc Nang Vu
Tam Anh general hospital of Hochiminh city, Viet Nam
P9-1. Transcatheter Stenting of a Tiny Patent Ductus Arteriosus for Right Heart Decompression in Advanced Pulmonary Arterial Hypertension
CVDongjin Lim
Seoul National Univ. Children's Hospital, Korea
P9-2. Congenital Portosystemic Shunt Treated By Interventional Device Closure : A Case Report
CVThuy Thuc Minh Pham
Tam Anh general hospital of Hochiminh city, Viet Nam
P9-3. Pulmonary endarterectomy in a patient with chronic thromboembolic pulmonary hypertension and antiphospholipid syndrome
CVKyungeun Ha
Gachon Univ., Korea
P9-4. Coexistence of Pulmonary Arterial Hypertension and Hepatopulmonary Syndrome in a Young Adult with Congenital Heart Disease: A Case Report
CVChih-Hsin Hsu
National Cheng Kung Univ., Taiwan
P10-1. Why we need 'RHJ'? From EASOPH's perspectives
CVYoshihiro Fukumoto
Kurume Univ. School of Medicine, Japan
P10-3. How do we develop 'RHJ' to the top soon? From EASOPH's perspectives
CVStephan Rosenkranz
Univ. of Cologne, Germany
P10-4. How do we develop 'RHJ' to the top soon? From Global perspectives
CV
B.S. in Medicine, Ulsan University, Ulsan, Republic of Korea
M.D. in Medicine, Ulsan University, Ulsan, Republic of Korea
Ph,D in Medicine, Ulsan University, Ulsan, Republic of Korea
Internship, Asan Medical Center
Residency, Department of Internal Medicine, Asan Medical Center
Clinical fellowship, Department of Pulmonology and Critical Care Medicine, Asan Medical Center
Assistant Professor, Department of Pulmonology and Critical Care Medicine, Asan Medical Center
Pulmonary hypertension
Venous thromboembolism
Airway disease
1993년 3월 ~ 1999년 2월 고려대학교 의과대학 의학사
2002년 3월 ~ 2004년 2월 고려대학교 의과대학 대학원 의학 석사 (내과학)
2004년 3월 ~ 2007년 2월 고려대학교 의과대학 대학원 의학 박사 (순환기내과)
1999년 3월 ~ 2000년 2월 고려대학교 병원 수련의
2000년 3월 ~ 2004년 2월 고려대학교 병원 내과 전공의
2004년 3월 ~ 2007년 2월 고려대학교 병원 순환기 내과 전임의/임상강사
2007년 5월 ~ 2009년 4월 Brigham and Women’s Hospital Research Fellow
2009년 5월 ~ 2010년 2월 인하대학교 병원 심장내과 임상강사
2010년 3월 ~ 2014년 2월 인하대학교 병원 심장내과 조교수
2014년 3월 ~ 2019년 2월 인하대학교 병원 심장내과 부교수
2018년 ~ 2019년 Brigham and Women’s Hospital Visiting Associate Professor
2019년 3월 ~ 현재 인하대학교 병원 심장내과 교수
대한내과학회 현) 윤리위원
대한심장학회 현) 편집위원, 정책위원
한국심초음파학회 현) 홍보이사
대한심부전학회 현) 국제교류이사
대한고혈압학회 현) 홍보위원
Professor Aldalaan earned his medical degree from King Saud University. He completed residencies in internal medicine at King Faisal Specialist Hospital & Research Centre and Duke University Medical Center. He then completed a pulmonary and critical care fellowship at the University of Virginia.
Abdullah Moshin Aldalaan, MBBS, is Director of the Pulmonary Hypertension Program of Excellence and a Consultant Pulmonologist at the King Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia. He also serves as a Professor in the College of Medicine at Alfaisal University, also located in Riyadh. In addition to his current role as President of the Saudi Association for Pulmonary Hypertension, Dr. Aldalaan has held leadership positions in numerous professional societies focused on respiratory disease and has lectured nationally and internationally.
Dr. Aldalaan established the lung transplant program at King Faisal Specialist Hospital & Research Centre in 2003. He also established the institution’s pulmonary hypertension (PH) treatment program, which is the only program in the area providing comprehensive diagnostic and therapeutic protocols for patients with PH. The program offers all available internationally recognized medical interventions for PH and has become a region-wide reference center for pulmonary hypertension education and treatment.
Dr. Aldalaan also is an active clinical trialist and has published more than 50 papers in peer-reviewed journals.
Recent publication of note:
Aldalaan A, Saleemi SA, Weheba I, et al. Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT). Pulm Circ. 2022;12:e12083, doi: 10.1002/pul2.12083.
Apr 1982- Mar 1988 MD; Okayama University Medical School
May 1988- Apr 1990 National Okayama Hospital, Department of Internal Medicine, Residency
May 1990- Apr 1993 National Cardiovascular Center, Department of Cardiology, Residency
Sep 2000 PhD; Okayama University Graduate School of Medicine and Dentistry
Okayama University Graduate School of Medicine and Dentistry, Department of Cardiology; Associate Professor (May 2000- Apr 2003)
National Hospital Organization, Okayama Medical Center, Department of Cardiology; Director (May 2003- Mar 2020, Department of Clinical Science; Director (May 2010- Mar 2019), Entire Medical Departments; Director (Apr 2019 - Mar 2021), Vice President (Apr 2021 – active)
clinical and physiological aspects of pulmonary hypertension
diagnosis and treatment of Group I PH
Interventional treatment of Group IV PH
JACC Cardiovasc Interv. 2024;17:707-708. doi: 10.1016/j.jcin.2023.11.022
Eur Respir J. 2024. doi: 10.1183/13993003.01294-2024
Can J Cardiol. 2024. doi: 10.1016/j.cjca.2024.05.003
J Heart Lung Transplant. 2024. doi: 10.1016/j.healun.2024.05.007
Circulation. 2024. doi: 10.1161/CIRCULATIONAHA.124.068610
2004-2006 Postdoctoral Fellow, ANTOINE BECLERE Hospital, Université Paris-Sud (Paris XI, South Paris University), France
1994-1998 Doctor of Medicine (M.D.) in Internal Medicine (Cardiovascular Diseases), Peking Union Medical College (PUMC), China
1989-1994 Bachelor of Medicine (M.B.) in Clinical Medicine, Weifang Medical University, China
Zhi-Cheng Jing is Full Professor of Medicine, the Director of Cardiology Department in Guangdong Provincial People’s Hospital and the Vice-president of Guangdong Cardiovascular Institute. He is the Associate Editor of Journal of Thrombosis and Haemostasis, the Associate Editor of Heart, the Asia-Pacific Regional Editor of JACC, the deputy editor in chief of Chinese Journal of Cardiology, and the Section Editor of JACC Asia.
Pulmonary Hypertension (PH)
Pulmonary Hypertensive Crisis
Pulmonary Embolism (PE)
Right Heart Circulation
Congenital Heart Disease (CHD)
1. Zhou YP, Wei YP, Yang YJ, et al. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. J Am Coll Cardiol. 2022;79(15):1477-1488.
2. Zhang ZJ, Liu C, Ma JL, et al. Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2024;84(12):1092-1103.
3. Wu XH, He YY, Chen ZR, et al. Single-cell analysis of peripheral blood from high-altitude pulmonary hypertension patients identifies a distinct monocyte phenotype. Nat Commun. 2023;14(1):1820. Published 2023 Mar 31.
4. Yan Y, He YY, Jiang X, et al. DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension. Sci Adv. 2020;6(50):eaba2470. Published 2020 Dec 9.
Visiting Scholar , University of Chicago Medical Center
PhD, Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan
Master Degree, Pulmonary Vascular Disease, University of Bologna, Bologna, Italy
MD, China Medical College, Taichung, Taiwan
2022- Clinical Professor, National Cheng Kung University
2023-, Deputy Superintendent, National Cheng Kung University Hospital
2020-2023 Medical Secretory, National Cheng Kung University Hospital
2019-2020 Deputy Superintendent, National Cheng Kung University Hospital Dou-Liou Branch
2004 Clinical Fellow, Cardiac Transplant Program, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center
Pulmonary Hypertension
Heart Failure
Heart Transplant Care
Critical Care
Post Resuscitation Care
Prof. Dr. med. Stephan Rosenkranz completed his Doctoral dissertation at Justus-Liebig-Universität Gießen, Gießen, Germany; a Post-doctoral fellowship at Harvard Medical School, Boston, Massachusetts, USA; and a residency and research fellowship at the Klinik III für Innere Medizin (Dept. of Cardiology), University of Cologne, Germany.
Prof. Dr. med. Stephan Rosenkranz currently holds the posts of Chair, Cologne Cardiovascular Research Center (CCRC); Full Professor of Cardiology (“Cardiopulmonary interaction”), University of Cologne; Head of Expert Center on Pulmonary Hypertension; Associate editor of European Journal of Heart Failure, Cardiovascular Research, Current Heart Failure Reports; and as a reviewer for numerous scientific journals, including Journal of the American Medical Association, Lancet, European Heart Journal.
Prof. Dr. med. Stephan Rosenkranz has experience in numerous clinical trials in the field of heart failure and pulmonary hypertension (phase I, II, III, IV) and is Head ("Principal Investigator") of the working group on "Molecular Cardiology," with a research focus of Signal transduction and pathobiological relevance of tyrosine kinases in cardiovascular disease.
Most recently: Rosenkranz S, Ghofrani HA, Hoeper MM, et al. Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities:
Data from interventional clinical trials [published correction appears in J Heart Lung Transplant.
2025:S1053-2498(25)01764-4. doi: 10.1016/j.healun.2025.02.1679.]. J Heart Lung Transplant. 2025;44(2):135-146. doi:10.1016/j.healun.2024.08.018
College: Harvard University, 1989, A.B. (Magna Cum Laude, Biology)
Medical School: University of Chicago Pritzker School of Medicine, 1994, M.D.
Internship: University of Chicago, Internal Medicine, 1994-1995
Residency: University of California San Francisco, Anesthesiology, 1995-1996
Residency: University of Chicago, Internal Medicine, 1996-1998
Fellowship: University of California San Diego, Pulmonary and Critical Care Medicine, 1998-2001
Faculty at UCSD since fellowship completion in 2001. Currently Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine. Section Chief of Pulmonary Vascular Medicine. Medical Director of Pulmonary Thromboendarterectomy Program. Previously fellowship program director 2009-2017. Since 2017, primary focus and administrative efforts at UCSD has been on leading our Pulmonary Vascular Medicine section.
1. Evaluation and treatment of pulmonary arterial hypertension
2. Interventional and medical management of chronic thromboembolic disease
3. Perioperative management following pulmonary thromboendarterectomy
4. Balloon pulmonary angioplasty for chronic thromboembolic disease
5. Clinical trials in pulmonary hypertension
As of Oct 2024: 117 peer-reviewed publications on pulmonary hypertension including, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Lead author for the 5th, 6th, and 7th World Symposium on Pulmonary Hypertension task force on chronic thromboembolic pulmonary hypertension
1998-2004 Pusan National University, College of Medicine, Medicine, Bachelor
2005~2007 Pusan National University, College of Medicine, Internal medicine, MMed
2012~2013 Pusan National University, College of Medicine, Internal medicine, Ph.D.
Feb 2004 Korean Medical License (No. 82164)
Mar 2009 Korean Board of Internal Medicine (No. 11607)
Oct 2015 Korean Subspecialty Board of Cardiology (No. 2-15-1019)
Mar 2021~ present: Assistant Professor, Internal Medicine (Division of Cardiology), Pusan National University Yangsan Hospital, Yangsan, Korea
Echocardiography,
Pulmonary Hypertension,
Hypertension / Dyslipidemia,
Cardiac amyloidosis / Cardiac Sarcoidosis
1. Value of Coronary Angiography in the Cardiac Myxoma. Clin Anat. 2019 Nov 21. doi: 10.1002/ca.23527
2. Mitral Loop Cerclage Annuloplasty for Secondary Mitral Regurgitation: First Human Results. JACC Cardiovasc Interv. 2017 Mar 27;10(6):597-610
3. Prognostic Significance of Presenting Blood Pressure in Patients with ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Am J Hypertens. 2015 Jun;28(6):797-805.
4. Right Cardiac Catheterization Using the Antecubital Fossa Vein in Korean Patients. Korean Circ J. 2016 Mar;46(2):207-12.
1992.3-1998.2: Seoul National University, College of Medicine. Received the certificate of medical doctor
2002.3-2007.2: Graduate School of Seoul National University, College of Medicine Received the degree of Master in Pediatrics
2007.3-2010.2 Graduate School of Seoul National University, College of Medicine Received the degree of Ph.D.in Pediatrics
2021.3- present: Professor Department of Pediatrics, Seoul National University Children’s Hospital Seoul National University, College of Medicine
2013.10- 2021.2: Associate Professor, Department of Pediatrics, Seoul National University Children’s Hospital
2013.3-2014.2: Research Fellowship Division of Interventional Cardiology, Department of Pediatrics, Boston Children’s Hospital, USA
2008.3- 2013.9: Assistant Professor, Department of Pediatrics, Seoul National University Children’s Hospital
Pediatric cardiac intervention
Pulmonary hypertension
Cardiomyopathy and heart transplantation
Kawasaki disease
Adult congenital heart disease
1. Park WY, Kim GB, Lee SY, Kim AY, Choi JY, Jang SI, Kim SH, Cha SG, Wang JK, Lin MT, Chen CA. The adaptability of the Pulsta valve to the diverse main pulmonary artery shape of native right ventricular outflow tract disease. Catheter Cardiovasc Interv. 2024 Feb 11.
2. Lee SY, Kim GB, Kim SH, Jang SI, Choi JY, Kang IS, Kim YH. Mid-term outcomes of the Pulsta transcatheter pulmonary valve for the native right ventricular outflow tract. Catheter Cardiovasc Interv. 2021 Jul 6. doi: 10.1002/ccd.29865
3. Kim GB, Song MK, Bae EJ, Park EA, Lee W, Lim HG, Kim YJ. Successful Feasibility Human Trial of a New Self-Expandable Percutaneous Pulmonary Valve (Pulsta Valve) Implantation Using Knitted Nitinol Wire Backbone and Trileaflet α-Gal-Free Porcine Pericardial Valve in the Native Right Ventricular Outflow Tract. Circ Cardiovasc Interv. 2018 Jun;11(6):e006494
Feb ’10 Graduate from Chung-Ang University, College of Medicine
Feb ’19 Master of Pediatrics from Seoul National University, College of Medicine
Feb ’21 Ph.D course from Seoul National University, College of Medicine
Mar ‘10~ Feb ’11 : Internship at Seoul National University Hospital
Mar ‘11~ Feb ’15 : Residency in Department of Pediatrics at Seoul National University Hospital
Mar ‘15~ Feb ’17 : Clinical Fellow of Department of Pediatric Cardiology at Seoul National University Hospital
Mar ‘17~ : Clinical Assistant Professor, Department of Pediatric Cardiology at Gachon University Gil Medical center
Mar ‘23~ : Assistant Professor, Department of Pediatric Cardiology at Gachon University Gil Medical center
Pediatric congenital heart disease
Adult congenital heart disease
Heart failure
Pulmonary hypertension
Kawasaki disease
Arrhythmia
Ahn KJ, Song MK, Lee SY, Yoon JK, Kim GB, Oh S, et al. The outcome of Long QT syndrome, a Korean single center study. Korean Circulation Journal. 2022;52(10):771-81.
Yeo J, Shin N, Ahn K-J, Seo M, Jang AY, Kim M, et al. Pulmonary arterial hypertension due to antiphospholipid syndrome initially mimicking chronic thromboembolic pulmonary hypertension. Clinical Hypertension. 2022;28(1):1-4.
Oh S, Jung J-H, Ahn K-J, Jang AY, Byun K, Yang PC, et al. Stem Cell and Exosome Therapy in Pulmonary Hypertension. Korean Circulation Journal. 2022;52(2):110-22.
Ahn KJ, Yu J, Jang AY, Kim D-H, Kwan J, Chung W-J. Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients. Yonsei Medical Journal. 2021;62(5):391.
Ahn KJ, Song MK, Kim GB, Kim WH, Bae EJ. Successful catheter ablation for ventricular tachycardia after cone procedure in Ebstein anomaly. HeartRhythm Case Rep. 2019 Nov 18;6(2):106-109.
Ahn KJ, Jang AY, Park SJ, Chung W-J. 15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation. Clinical Hypertension. 2019;25(1):1-4
Undergraduate/college: Davidson College, 2007-2011 – Bachelor of Science (BS)
Medical school: Jefferson Medical College at Thomas Jefferson University, 2011-2015 – Medical Degree (MD)
Internship/Residency: University of California San Diego, 2015-2018 – Internal Medicine
Fellowship: University of California San Diego, 2018-2021 – Pulmonary and Critical Care Medicine
Assistant Clinical Professor of Medicine, Pulmonary and Critical Care Medicine: University of California San Diego, 2021-2025
Staff Physician, Pulmonary and Critical Care Medicine: Veterans Affairs San Diego Medical Center, 2021-2023
Associate Clinical Professor of Medicine, Pulmonary and Critical Care Medicine: University of California San Diego, 2025-present
Chronic thromboembolic pulmonary hypertension (CTEPH)
Pulmonary arterial hypertension (PAH)
Exercise pulmonary hypertension/ invasive cardiopulmonary exercise test
1. Yang JZ, Poch DS, Ang L, Mahmud E, Bautista MA, Alotaibi M, Fernandes TM, Kerr KM, Papamatheakis DG, Kim NH. “Tricuspid annular plane systolic excursion to pulmonary artery systolic pressur ratio in chronic thromboembolic pulmonary hypertension improves with balloon pulmonary angioplasty.” Pulmonary Circulation. October 2024;14(4):e12452.
2. Yang JZ, Kim NH, Kligerman S, Fernandes TM, Papamatheakis DG, Poch DS, Alotaibi M, Pretorius VG, Madani MM, Kerr KM. “Outcomes Associated with Catheter-Directed Therapies in Chronic Thromboembolic Pulmonary Hypertension: Cautionary Tales from a Single-center Case Series.” CHEST Pulmonary. September 2023; 1(2):100009. https://doi.org/10.1016/j.chpulm.2023.100009.
3. Yang J, Madani MM, Mahmud E, Kim NH. “Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension.” CHEST. August 2023; 164 (2): 490-502.
4. Yang JZ, Odish MF, Mather H, Pebley N, Wardi G, Kim NH, Papamatheakis DG, Poch DS, Fernandes TM, Sell RE. “Outcomes of Cardiopulmonary Resuscitation in Pulmonary Arterial Hypertension.” Pulmonary Circulation. April 2022. 12(2):e12066.
5. Yang JZ, Fernandes TM, Kim NH, Kerr K, Poch DS, Lombardi S, Melber D, Kelly T, Papamatheakis D. “Pregnancy and pulmonary arterial hypertension: A case series with long term follow up and literature review.” American Journal of Obstetrics & Gynecology: Maternal-Fetal Medicine. July 2021. 3(4):100358.
Nanjing Medical University (China)
Doctor of Medicine, Chief physician, Professor, doctoral supervisor
Vice Chairman of the Heart Failure Committee of China Research Hospital
Youth member, Heart Rhythm Branch, Chinese Medical Doctor Association
Deputy Chairman of the heart failure Committee of Jiangsu Medical Association
Deputy head of pacing Group, Electrophysiology and Pacing Branch Jiangsu Medical Association
Diagnosis and treatment of arrhythmia, heart failure and pulmonary hypertension.
Pacemaker, CRT, ICD implantation, RHC, and related application of basic research.
Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomized PADN-CFDA Trial. JACC Cardiovasc Interv. 2022 Dec 12;15(23):2412-2423. doi: 10.1016/j.jcin.2022.09.013. Epub 2022 Sep 18.
3Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension: Results From PADN-5 Trial. JACC Heart Fail 2023 Aug;11(8 Pt 2):1135-1146. doi: 10.1016/j.jchf.2023.05.016. Epub 2023 Jun 21.
Pulmonary Artery Denervation: Update on Clinical Studies. Curr Cardiol Rep. 2019 Sep 5;21(10):124. doi: 10.1007/s11886-019-1203-z.